A case of checkpoint inhibitor-induced celiac disease

BACKGROUND: Immune checkpoint inhibitors (ICIs) have now become standard of care treatment for many malignancies. ICIs are associated with unique immune mediated adverse events (irAEs) due to dysregulation of immune activation. As treatment with ICIs is becoming more common, rare irAEs are also bein...

Descripción completa

Detalles Bibliográficos
Autores principales: Alsaadi, Dana, Shah, Neil J., Charabaty, Aline, Atkins, Michael B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6683380/
https://www.ncbi.nlm.nih.gov/pubmed/31383006
http://dx.doi.org/10.1186/s40425-019-0694-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6683380/
https://www.ncbi.nlm.nih.gov/pubmed/31383006
http://dx.doi.org/10.1186/s40425-019-0694-x

Ejemplares similares